pipeline restructuring – Talk Bio

Actionable Insights Powered by AI

Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program

2 weeks ago talkbio0Tagged BBI-355, BBI-825, Bio, Boundless, CHEK1 protein, human, Clinical Trials, Combined Modality Therapy, Inhibitor, layoffs, pipeline restructuring, ribonucleoside-diphosphate reductase activity, Solid Neoplasm

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring